Kowal Investment Group LLC Sells 315 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Kowal Investment Group LLC decreased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 7.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,208 shares of the biopharmaceutical company’s stock after selling 315 shares during the quarter. Kowal Investment Group LLC’s holdings in Gilead Sciences were worth $308,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in GILD. Etesian Wealth Advisors Inc. boosted its position in shares of Gilead Sciences by 0.7% in the 4th quarter. Etesian Wealth Advisors Inc. now owns 18,318 shares of the biopharmaceutical company’s stock worth $1,486,000 after purchasing an additional 128 shares during the last quarter. Financial Counselors Inc. lifted its holdings in Gilead Sciences by 1.5% during the fourth quarter. Financial Counselors Inc. now owns 8,862 shares of the biopharmaceutical company’s stock worth $718,000 after acquiring an additional 128 shares in the last quarter. Revolve Wealth Partners LLC lifted its holdings in Gilead Sciences by 3.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 3,607 shares of the biopharmaceutical company’s stock worth $292,000 after acquiring an additional 130 shares in the last quarter. Steph & Co. lifted its holdings in Gilead Sciences by 1.9% during the fourth quarter. Steph & Co. now owns 7,548 shares of the biopharmaceutical company’s stock worth $611,000 after acquiring an additional 142 shares in the last quarter. Finally, First Affirmative Financial Network lifted its holdings in Gilead Sciences by 3.5% during the first quarter. First Affirmative Financial Network now owns 4,342 shares of the biopharmaceutical company’s stock worth $318,000 after acquiring an additional 147 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Analysts Set New Price Targets

GILD has been the topic of several recent analyst reports. Maxim Group reduced their target price on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a report on Wednesday, May 1st. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a report on Friday, April 26th. Oppenheimer reiterated an “outperform” rating and set a $105.00 target price on shares of Gilead Sciences in a report on Friday, April 19th. Robert W. Baird reiterated a “neutral” rating and set a $80.00 target price on shares of Gilead Sciences in a report on Thursday, June 20th. Finally, Morgan Stanley dropped their price target on Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating on the stock in a research note on Friday, April 26th. Twelve research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $83.47.

Gilead Sciences Price Performance

NASDAQ:GILD opened at $68.64 on Tuesday. The company has a debt-to-equity ratio of 1.31, a quick ratio of 0.94 and a current ratio of 1.08. The stock’s 50-day simple moving average is $65.98 and its 200 day simple moving average is $72.51. The company has a market cap of $85.52 billion, a P/E ratio of 190.67, a P/E/G ratio of 2.92 and a beta of 0.18. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $87.86.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.49) by $0.17. The firm had revenue of $6.69 billion for the quarter, compared to the consensus estimate of $6.36 billion. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. The business’s revenue was up 5.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.37 earnings per share. As a group, sell-side analysts forecast that Gilead Sciences, Inc. will post 3.75 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, June 27th. Shareholders of record on Friday, June 14th were given a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a yield of 4.49%. The ex-dividend date was Friday, June 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 855.56%.

Insiders Place Their Bets

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $68.63, for a total transaction of $137,260.00. Following the transaction, the insider now owns 96,380 shares of the company’s stock, valued at $6,614,559.40. The sale was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 0.29% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.